EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #39
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
Kaizaki-Mitsumoto, A; Noguchi, N; Yamaguchi, S; Odanaka, Y; Matsubayashi, S; Kumamoto, H; Fukuhara, K; Funada, M; Wada, K; Numazawa, S. Three 25-NBOMe-type drugs, three other phenethylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market. Forensic Toxicol., 1 Jan 2016, 34 (1), 108–114. 854 kB. https://doi.org/10.1007/s11419-015-0293-6
Dunne, SJ; Rosengren-Holmberg, JP. Quantification of synthetic cannabinoids in herbal smoking blends using NMR. Drug Test. Analysis, 1 May 2017, 9 (5), 734-743. 988 kB. https://doi.org/10.1002/dta.2032
Hess, C; Murach, J; Krueger, L; Scharrenbroch, L; Unger, M; Madea, B; Sydow, K. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples. Drug Test. Analysis, 1 May 2017, 9 (5), 721-733. 267 kB. https://doi.org/10.1002/dta.2030 #MAB-CHMINACA LC,MS
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #8. ADB-CHMINACA
EMCDDA. Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2018. 1.1 MB. #ADB-CHMINACA
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution. In Handbook of Experimental Pharmacology; , Springer Berlin Heidelberg, 1 Jan 2018; . 1.2 MB. https://doi.org/10.1007/164_2018_144 #46